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yeasts have rewired many regulatory 
networks, such that processes as 
diverse as ribosomal protein gene 
regulation, galactose metabolism and 
mating-type switching, which appear 
to be very similar at the physiological 
level, are regulated by different 
transcription factors that bind to 
different regulatory sequences. 
Despite its evolutionary distance 
to S. cerevisiae being relatively short, 
C albicans, like other members of 
the ‘CUG’ clade, has a genetic code 
with a non-standard codon — CUG 
encodes serine rather than the 
conventional leucine — obviating the 
direct use of many genetic markers 
from heterologous organisms such as 
S. cerevisiae. This obstacle has been 
overcome by the development of 
codon-optimized markers, fluorescent 
proteins and other epitope tags, 
which can be inserted into the 
genome by several approaches 
all ultimately involving homology-
based recombination. These tools 
have led to many of the important 
advances in our understanding of the 
molecular mechanisms specifying 
mating, white-opaque switching, 
biofilm formation and other processes 
important for pathogenicity and 
virulence. There are clearly many 
more to come.
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PrimerIn eukaryotic cells, the endoplasmic 
reticulum (ER) is a membrane-enclosed 
interconnected organelle responsible 
for the synthesis, folding, modification, 
and quality control of numerous 
secretory and membrane proteins. 
The processes of protein folding and 
maturation are highly assisted and 
scrutinized but are also sensitive to 
changes in ER homeostasis, such 
as Ca2+ depletion, oxidative stress, 
hypoxia, energy deprivation, metabolic 
stimulation, altered glycosylation, 
activation of inflammation, as well as 
increases in protein synthesis or the 
expression of misfolded proteins or 
unassembled protein subunits. Only 
properly folded proteins can traffic 
to the Golgi apparatus, whereas 
those that misfold are directed to 
ER-associated degradation (ERAD) 
or to autophagy. The accumulation 
of unfolded/misfolded proteins in 
the ER activates signaling events 
to orchestrate adaptive cellular 
responses. This unfolded protein 
response (UPR) increases the ER 
protein-folding capacity, reduces global 
protein synthesis, and enhances ERAD 
of misfolded proteins. 
In mammals, the UPR is signaled 
through three ER transmembrane 
protein sensors (Figure 1): inositol-
requiring kinase 1 (IRE1), pancreatic 
ER eIF2a kinase (PERK), and activating 
transcription factor 6 (ATF6). The 
luminal domain of each sensor 
responds to the level of unfolded/
misfolded protein in the ER. If the cell 
cannot resolve the protein-folding 
defect, cell-death signaling pathways 
are activated. As our understanding 
of ER protein-folding pathways and 
the mechanisms of UPR signaling of 
adaptive and apoptotic responses 
has grown, so has the significance 
of their impact on the etiology 
of multiple human pathologies, 
including metabolic syndrome, 
neurodegenerative disorders, 
inflammatory disease and cancer. With 
this armamentarium of knowledge, it 
is now possible for rational design of therapeutics to target protein-folding 
pathways and UPR signaling to resolve 
protein misfolding in disease states 
in a manner that was not previously 
conceivable.
IRE1–XBP1 
The most conserved branch of the 
UPR is mediated by IRE1, a type I 
transmembrane protein with both a 
serine/threonine kinase domain and 
an endoribonuclease (RNase) domain 
in its cytosolic portion. In yeast, Ire1p 
is the only identified ER stress sensor. 
There are two IRE1 homologues 
in mammals: IRE1a is expressed 
ubiquitously, whereas IRE1b expression 
is mostly restricted to the intestinal 
epithelium. 
Two models have been proposed 
for the activation of IRE1/Ire1p. The 
first is a competition-binding model 
that posits unfolded and/or misfolded 
proteins in the ER lumen compete with 
Ire1p for binding to the chaperone BiP. 
Ire1p binding to BiP inhibits signaling, 
whereas Ire1p released from BiP 
forms homodimers and oligomers that 
promote trans-autophosphorylation 
and RNase activation. Alternatively, 
since the crystal structure of the 
yeast Ire1p luminal domain revealed 
the presence of a peptide-binding 
groove similar to that of major 
histocompatibility class I molecules, it 
was proposed that unfolded/misfolded 
proteins directly bind to the amino-
terminal luminal domain of Ire1p to 
induce dimerization. A recent study 
showed that unfolded proteins and 
hydrophobic peptides bind to the 
core luminal domain of Ire1p, which 
then undergoes dimerization in vitro. 
In contrast, the peptide-binding cleft 
in the crystal structure of the luminal 
domain of human IRE1a is not solvent 
accessible and the luminal domain 
does not interact with unfolded 
proteins in vitro. A mutant form of 
IRE1a that cannot bind to BiP is 
able to spontaneously dimerize and 
activate kinase/RNase activities in the 
absence of ER stress, suggesting that 
mammalian IRE1a may be released 
from BiP but may not require peptide 
binding for activation. 
The luminal domain of IRE1a forms 
homodimers in the plane of the ER 
membrane, juxtaposing the kinase 
domains for trans-autophosphorylation 
to stimulate the kinase and RNase 
activities. These activities initiate the 
removal of a 26 base intron from the 
mRNA encoding X-box-binding protein 
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Figure 1. The unfolded protein response in mammals. See main text for details.1 (XBP1), resulting in a translational 
frameshift that generates a 41 kDa 
CREB/ATF basic leucine zipper 
(bZiP)-containing transcription factor. 
In addition to selective cleavage of 
the Xbp1 mRNA, IRE1 degrades a 
subset of ER-localized mRNAs in 
Drosophila and in mammalian cells in 
a stress-dependent manner — termed 
regulated IRE1-dependent decay of 
mRNAs (RIDD) — thereby reducing 
protein synthesis to alleviate ER stress. 
Analysis of RIDD targets revealed a 
consensus CUGCAG sequence motif 
within a stem–loop structure. Recently, 
a small molecule that specifically 
binds to and inhibits the activity of 
the IRE1 RNase domain was shown 
to abolish Xbp1 mRNA splicing and 
RIDD, impeding the expansion of the 
protein secretory capacity. Previous 
studies suggested that IRE1b is less 
active than IRE1a in cleaving Xbp1 mRNA; instead, it can cleave 28S 
ribosomal RNA to attenuate mRNA 
translation and can degrade the mRNA
encoding microsomal triglyceride 
transfer protein to limit chylomicron 
production and lipid absorption in the 
small intestine.
As a potent transcription activator, 
XBP1 binds to the UPR element 
(UPRE) and to the ER stress-response 
elements I and II (ERSE-I and ERSE-II) 
in the promoter regions of target genes
Previous studies suggested that XBP1 
induces the expression of a wide range
of genes that orchestrate ER protein 
folding, secretion, quality control and 
ERAD, and activates phospholipid 
biosynthesis and ER expansion upon 
ER stress. 
IRE1a–XBP1 signaling plays an 
important role in a wide spectrum 
of biological processes, including 
differentiation, metabolism,  
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inflammation, tumorigenesis and 
neurodegeneration. Whole-body 
deletion of Ire1a or Xbp1 in mice 
is embryonic lethal at 12.5 days 
of gestation. XBP1 is essential for 
liver development by inducing the 
expression of a-fetoprotein and severa
acute phase response genes that 
promote hepatocyte differentiation, 
growth and prevent apoptosis. IRE1a 
is activated dramatically in murine 
placenta, while loss of IRE1a reduces 
vascular endothelial growth factor-
A (VEGF-A) expression with severe 
dysfunction of the labyrinth, which has 
a highly developed network of blood 
vessels that are essential for nutrient 
uptake during fetal development. 
XBP1 also contributes to expression 
of the placental carcinoembryonic 
antigen family of proteins. In addition, 
IRE1a–XBP1 is required for plasma 
cell differentiation, development 
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and survival of dendritic cells, 
the proinflammatory response in 
macrophages, the maturation of 
digestive enzyme-secreting zymogenic 
cells in the stomach, and the normal 
function and homeostasis of Paneth 
cells, a secretory intestinal epithelial 
cell essential for innate immunity and 
host defense. 
Recently, IRE1a–XBP1 signaling 
was linked to numerous human 
diseases, including several cancers, 
b-cell failure, obesity, rheumatoid 
arthritis, inflammatory bowel disease, 
vitiligo, amyotrophic lateral sclerosis 
(ALS), and Huntington’s disease (HD). 
Interestingly, the deficiency of XBP1, 
which functions as a pro-survival 
transcription factor in multiple disease 
models, impedes the progression 
of both ALS and HD by enhancing 
macroautophagy of mutant SOD1 or 
huntingtin. 
Several pleiotropic transduction 
pathways have been invoked in 
XBP1-mediated UPR signaling. Recent 
studies demonstrated that p38 MAP 
kinase and the regulatory subunits of 
phosphoinositide 3-kinase regulate 
the UPR and insulin sensitivity by 
increasing the nuclear translocation 
of XBP1. In Caenorhabditis elegans, 
IRE-1–XBP-1 plays the predominant 
role in UPR signaling, similar to 
Saccharomyces cerevisiae, with PEK 
(the C. elegans homolog of mammalian 
PERK) and ATF6 being less important. 
In C. elegans, XBP-1 is essential for 
larval host protection against ER stress 
induced by the immune response to 
bacterial infection. Moreover, in daf-2 
worms that are mutant in insulin/IGF-
1 signaling, XBP-1 collaborates with 
the FOXO transcription factor DAF-16 
to enhance ER stress resistance and 
promote longevity.
As a protein kinase, IRE1a was 
proposed to integrate UPR signaling 
with inflammatory responses. Upon 
ER stress, phosphorylation of IRE1a 
in the cytosolic domain stimulates 
its interaction with tumor necrosis 
factor a (TNFa) receptor-associated 
factor 2 (TRAF2), an adaptor protein 
in the TNFa signaling pathway. The 
IRE1a–TRAF2 complex recruits IkB 
kinase (IKK), which in turn leads to 
the phosphorylation and degradation 
of IkB, resulting in NF-kB activation 
and upregulation of its downstream 
inflammatory pathways. The IRE1a–
TRAF2 complex also recruits apoptosis 
signaling kinase (ASK1), which 
activates c-Jun N-terminal kinase (JNK) to stimulate proinflammatory response 
signaling via the phosphorylation of the
AP1 transcription factor. Additionally, 
IRE1a–JNK was suggested to activate 
pro-apoptotic pathways and induce 
insulin resistance by phosphorylating 
insulin receptor substrate 1 and 2 in 
response to ER stress. 
PERK–eIF2a–ATF4–CHOP
PERK is a type I transmembrane 
protein with a cytosolic serine/
threonine kinase domain. Although the 
luminal domains of PERK and IRE1 
exhibit limited sequence homology, the 
predicted structure of the PERK luminal
domain is similar to that of the IRE1a 
luminal domain. Upon ER stress, the 
chaperone BiP is released from PERK, 
which then undergoes oligomerization 
and trans-autophophorylation. Indeed, 
the activation machinery of PERK 
is quite similar to that of IRE1a. The 
luminal domain of human PERK can 
replace the protein misfolding-sensing 
function of the luminal domain of 
yeast Ire1p, although yeast does not 
have a Perk gene. Activated PERK 
phosphorylates Ser51 of the a subunit 
of eukaryotic translation initiation factor
2 (eIF2a), which in turn attenuates 
translation initiation to reduce the ER 
protein-folding load. 
In mammals, three additional 
eIF2a kinases phosphorylate eIF2a 
at Ser51, each responding to a 
different stress: the double-stranded 
RNA-activated protein kinase (PKR) 
responds to viral infection, ER 
stress, and nutrient signals; general 
control non-derepressible-2 (GCN2) 
is activated during amino-acid 
starvation; and the heme-regulated 
inhibitor kinase (HRI) limits protein 
synthesis in heme-deficient erythroid 
cells, reduces oxidative stress, and 
promotes maturation and activation of 
macrophages. Generally, translation 
attenuation in response to ER stress 
is transient due to GADD34-directed 
dephosphorylation of eIF2a mediated 
by protein phosphatase PP1. This tight 
temporal balance of protein synthesis 
is essential for adaptation because, 
when protein folding is perturbed, 
increased transcription of adaptive 
functions requires mRNA translation to 
restore protein-folding functions.
The significance of eIF2a 
phosphorylation in mammals was 
highlighted by a number of studies. 
Transgenic mice bearing homozygous 
knock-in loss-of-function Ser51Ala 
mutation at the eIF2a phosphorylation  
 
site died within 18 hours of birth, due to 
severe hypoglycemia associated with 
defective gluconeogenesis in the liver. 
This was actually the first indication 
that ER stress is tightly linked with 
metabolic control. Later it was found 
that phospho-eIF2a is essential for 
optimal expression of many UPR genes 
and is critical for the maintenance 
of cellular homeostasis and normal 
function in multiple cell types, including 
fibroblasts, osteoblasts, hepatocytes, 
as well as pancreatic endocrine 
and exocrine cells. A recent study 
demonstrated that the absence of 
phospho-eIF2a in pancreatic b cells 
leads to a severe diabetic phenotype 
associated with heightened and 
dysregulated proinsulin translation, 
proinsulin misfolding, defective ER-to-
Golgi transport, diminished expression 
of b-cell-specific genes, an impaired 
ER stress response, increased 
oxidative damage and apoptosis.
In addition to global translational 
suppression, phospho-eIF2a selectively 
induces translation of several mRNAs, 
including that encoding activating 
transcription factor 4 (ATF4), a 39 kDa 
bZIP transcription factor that induces 
transcription of genes encoding ER 
chaperones, including BiP and GRP94, 
UPR-associated transcription factors, 
including XBP1, and intracellular 
trafficking machinery that is required 
for ER-to-Golgi trafficking of ATF6 
upon ER stress. ATF4 improves 
cellular homeostasis and function by 
inducing amino acid biosynthesis and 
transport, promoting anti-oxidative 
stress responses, and stimulating 
the expression of autophagy genes, 
including MAP1LC3B, ATG12, and 
BECN1. Recently, ATF4 was shown 
to orchestrate the proliferation and 
differentiation of chondrocytes and 
promote endochondral ossification, by 
transcriptional activation of the locally 
secreted factor Indian Hedgehog. 
In addition, ATF4 drives osteoblast 
differentiation and controls osteoblast 
functions, including bone formation, 
extracellular matrix mineralization, and 
bioactivity of osteocalcin. Transcription 
and translation of the cellular inhibitors 
of apoptosis (XIAP, cIAP1 and cIAP2) 
are also induced by PERK-mediated 
phosphorylation of eIF2a in response 
to ER stress.
One of the downstream targets 
of eIF2a–ATF4 is CCAAT/enhancer-
binding protein homologous protein 
(CHOP), a 29 kDa bZIP transcription 
factor whose promoter contains 
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by Atf6b have not been identified. 
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Figure 2. Endoplasmic reticulum stress in human disease. 
A number of human diseases are associated with ER protein-folding defects and the UPR. 
Studies of ER stress and the UPR should enhance our understanding of the pathogenesis of 
these diseases and open up new avenues to therapeutic approaches.the binding sites for several major 
transactivators of the UPR, including 
ATF4 and ATF6. CHOP is an important 
mediator of ER stress-induced 
apoptosis. CHOP activates a number 
of pro-apoptotic factors, including 
death receptor 5 (DR5), Bim (a pro-
apoptotic member of BCL-2 family), 
and telomere repeat binding factor 3 
(TRB3), and inhibits the anti-apoptotic 
protein BCL-2. Moreover, CHOP 
causes oxidative stress by inducing 
ERO1a, which transfers electrons 
from protein disulfide isomerase to 
O2 to produce H2O2. ERO1a also 
promotes Ca2+ release from the ER 
through the inositol 1,4,5-trisphosphate
receptor. Since Ca2+ is required 
for ER chaperone function and for 
protein folding, depletion of ER Ca2+ 
further disrupts protein folding. Ca2+ 
released from the ER is loaded into 
mitochondria leading to oxidative 
stress and pro-apoptotic signaling. In 
addition, CHOP induces transcription 
of Gadd34, which encodes a regulatory
subunit of PP1 that dephosphorylates 
eIF2a, thereby increasing protein 
synthesis. If CHOP is induced when 
protein folding is compromised, the 
increase in protein synthesis would 
accentuate oxidative stress and pro-
apoptotic signaling. Consistent with 
these observations, deletion of Chop is
protective against ER-stress-induced 
apoptosis in multiple cell types, 
including fibroblasts, pancreatic b cells
macrophages, and smooth muscle 
cells, and CHOP should therefore 
be considered a promising target for 
treating diseases such as cancer, 
type 2 diabetes, atherosclerosis, and 
diseases associated with protein 
misfolding. 
ATF6
ATF6 is a type II ER transmembrane 
protein with a CREB/ATF bZIP 
transcription factor domain at the 
amino terminus. Upon accumulation 
of unfolded protein in the ER, ATF6 
is released from BiP for trafficking 
to the Golgi apparatus where it is 
sequentially cleaved by site 1 and site
2 proteases at the transmembrane 
site, yielding a cytosolic fragment 
known as ATF6 p50, which migrates 
to the nucleus to activate gene 
expression. The process by which 
ER-localized bZIP transcription 
factors translocate from the ER to 
the Golgi for cleavage to produce 
functional forms is termed regulated 
intramembrane proteolysis (RIP).  
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Mammals have two ATF6 
homologues, ATF6a and ATF6b. 
In mammalian cells, ATF6a can 
function as a homodimer and bind to 
ERSE motifs in promoter regions to 
transactivate ER chaperone genes, 
such as Bip and p58IPK. Moreover, 
ATF6a can heterodimerize with XBP1 
in response to ER stress and induce 
the expression of ERAD components, 
such as EDEM, HERP and HRD1. 
Unlike mice lacking XBP1 and ATF4, 
Atf6a-null mice do not exhibit apparent 
abnormalities under normal conditions. 
However, ATF6a is essential for 
optimal protein folding, secretion, 
and degradation in response to ER 
stress. As a consequence, ATF6a-
deficient cells cannot recover from 
acute ER stress. Additionally, ATF6a 
was proposed to induce ER quality 
control genes by recruiting the CREB-
regulated transcription coactivator 
2 (CRTC2) to ER stress-inducible 
promoters, and to downregulate 
hepatic gluconeogenesis by disrupting 
the CREB–CRTC2 interaction, thereby 
diminishing CRTC2 binding to the 
promoters of gluconeogenic genes 
in hepatocytes. In contrast, Atf6b-
null mice do not have a significant 
phenotype, even when challenged with 
ER stress. To date, genes regulated Surprisingly, Atf6a and Atf6b double 
knockout mice die at a very early 
embryonic stage, suggesting that 
an overlapping function of the two 
isoforms is essential during early 
embryonic development. 
In addition to ATF6, additional 
RIP-regulated bZIP transcription 
factors have been identified, including 
Luman/CREB3, OASIS/CREB3L1, and 
CREBH/CREB3L3. ER stress induces 
both transcription and proteolytic 
processing of Luman, resulting in its 
binding to ERSE-II and induction of 
expression of the ERAD protein HERP. 
OASIS is proteolytically activated 
during ER stress. Similar to ATF4, 
OASIS plays an important role in bone 
formation. OASIS is highly expressed in 
osteoblasts, where it transactivates the 
gene encoding type I collagen through 
a UPRE-like sequence in the promoter 
region. Moreover, OASIS transcription 
is induced upon ER stress in astrocytes 
of the brain, where it activates 
expression of BiP and prevents ER 
stress-induced cell death. Recent 
studies demonstrated that OASIS is 
required for the terminal differentiation 
of colonic goblet cells and mucin 
secretion from these cells. CREBH, 
a hepatocyte-specific transcription 
factor, is induced by proinflammatory 
cytokines, including interleukin-6 and 
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upon ER stress. In contrast to ATF6a, 
CREBH does not induce UPR gene 
expression; instead, it induces 
the expression of genes encoding 
components of the systemic arm of 
the innate immune response — the 
acute phase response — including 
C-reactive protein and serum amyloid 
P component. Recent studies 
demonstrated that CREBH-mediated 
transcription is required for optimal 
gluconeogenesis and lipid metabolism 
in the liver. Importantly, mutant Crebh 
alleles that result in non-functional 
CREBH or reduced levels of CREBH 
were identified in patients with extreme
hypertriglyceridemia, indicating the 
physiological significance of CREBH in 
lipid homeostasis.
ER stress and the UPR in therapeutics
Since ER stress may contribute to 
the pathogenesis of multiple human 
diseases (Figure 2), this signaling 
nexus may be exploited as a 
therapeutic target for pharmacological 
intervention. Tauroursodeoxycholate 
(TUDCA) and 4-phenylbutyrate 
(PBA) alleviate ER stress by acting 
as chemical chaperones to prevent 
protein misfolding and aggregation in 
the cell. TUDCA and PBA are agents 
approved by the Food and Drug 
Administration (FDA) for the treatment 
of primary biliary cirrhosis and urea-
cycle disorders, respectively. Both 
compounds promote the folding and 
intracellular trafficking of the mutant 
Z allele of a1-antitrypsin and the 
D508 cystic fibrosis transmembrane 
regulator, and ameliorate type 2 
diabetes by reducing chronic ER stress
and insulin resistance in the tissues of 
animals and humans with metabolic 
syndrome. In addition, TUDCA and PBA
are in clinical trials for the treatment 
of many diseases that are associated 
with protein-folding defects and ER 
stress, including cystic fibrosis, ALS, 
HD, and spinal muscular atrophy. Given
the excellent safety profiles of both 
compounds in humans, these agents 
may be developed as novel therapies 
for these diseases by restoring cellular 
protein-folding homeostasis. 
Guanabenz is an FDA-approved drug 
for hypertension that selectively inhibits 
GADD34-mediated dephosphorylation 
of eIF2a and exerts a cytoprotective 
effect against ER stress by prolonging 
eIF2a phosphorylation and translation 
attenuation. As eIF2a phosphorylation 
is protective in many pathologic  
 
 
 
conditions such as b-cell failure, 
diabetes, Alzheimer’s disease, prion 
disease, and immune-mediated 
demyelination in the central nervous 
system, guanabenz may be a 
promising candidate for the treatment 
of these diseases. ER luminal Ca2+ 
is critical for proper protein folding 
and maturation, and Ca2+ leakage 
from the ER is sufficient to induce ER 
stress, mitochondrial damage and 
oxidative stress in the cell. Diltiazem 
and verapamil are FDA-approved 
hypertension drugs that stabilize ER 
Ca2+ levels and improve ER protein 
folding. Future studies should test 
the therapeutic potential of these 
compounds in ER stress-associated 
disease models. 
Multiple myeloma cells rely on the 
IRE1a–XBP1-mediated UPR to cope 
with the high burden of immunoglobulin 
folding and secretion. Human studies 
suggest that spliced Xbp1 mRNA 
(XBP1s) is an independent prognostic 
marker for multiple myeloma where 
patients with low XBP1s have a 
significantly higher survival rate. A small 
molecule that inhibits IRE1a RNase to 
prevent Xbp1 mRNA splicing enhanced 
apoptosis of multiple myeloma cells 
induced by proteosome inhibitors. This 
synergistic effect was associated with 
increased pro-apoptotic UPR signaling. 
Future studies should examine whether 
inhibition of Xbp1 splicing exhibits 
selective cytotoxicity toward other 
cancer cells with high protein secretory 
activity, such as mammary cancer cells 
and insulinoma cells. Given the critical 
role of IRE1a–XBP1 signaling in multiple 
normal cell types in vivo, it is important 
to examine whether the long-term use 
of IRE1a inhibitors will negatively affect 
the function of certain tissues/organs, 
including the pancreas, liver, and 
immune system.
In addition to pharmacological 
manipulations, forced expression of 
pro-survival UPR genes in specific 
tissues by gene therapy has shown 
promise for several neurodegenerative 
diseases. The local delivery of the Bip 
gene mitigated neuronal degeneration 
and disease symptoms of autosomal 
dominant retinitis pigmentosa 
and Parkinson’s disease in rodent 
models. The overexpression of the ER 
chaperone GRP94 alleviated spinal 
cord injury in a rat model.
Perspectives
Our recent insights indicate that 
protein-folding homeostasis in the ER plays critical roles in eukaryotic 
cell function and that the UPR is an 
essential regulatory hub that interacts 
with all aspects of cell signaling at 
the transcriptional, translational and 
post-translational levels. Despite all 
this progress, there is still a need 
to understand what factors limit ER 
protein-folding efficiency for specific 
proteins in different cell types. Our 
understanding of the impact of protein 
misfolding in the ER and the UPR has 
also extended to a broad spectrum 
of normal organismal physiological 
functions and pathological 
conditions. Future studies should 
further our understanding of how 
the UPR interacts with other signal 
transduction pathways in different 
cell types and the tissue-specific 
roles of the ER stress sensors, 
transducers, and effectors under 
various pathophysiological conditions. 
Protein misfolding in the ER and the 
UPR are promising therapeutic targets 
for multiple human diseases. We can 
now test the therapeutic potential of 
these targets by generating tissue-
specific deletion/overexpression 
animal models and by identifying 
small molecules that specifically 
target selective UPR components. 
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